Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bill Revising ASP Calculation Surfaces Again In House; Medicare Cost Question Remains

This article was originally published in The Pink Sheet Daily

Executive Summary

Bipartisan bill from Reps. Whitfield and Green would permanently exclude prompt pay discounts from the calculation of average sales price for drugs used in Medicare Part B.

You may also be interested in...



Testing Part B Payment Cuts: Sequester Means Providers Get ASP+4%

Cutting the payment level for Medicare Part B drugs is a perennial budget proposal, but never gets very far in Congress. Now, thanks to the sequester, Part B payments have been cut from ASP+6% to ASP+4.3%. Will it stick?

Oncology Groups Ask HHS To Revise How Sequester’s Cuts Are Applied To Part B Drugs

A 2% cut is being applied first to the average sales price for drugs reimbursed by Medicare Part B, and then another 2% is taken out of the 6% add-on. The approach compounds the overall reduction to a level that far exceeds the 2% Medicare cut required by sequestration, according to the groups.

ASP Calculation Could Get Temporary Revision Under House Reform Bill

Drug wholesalers and physicians could get their wish of having the average sales price calculation for Medicare Part B drugs exclude customary prompt pay discounts, under a provision added to the House Energy and Commerce Committee's portion of health care reform legislation. But the fix, if kept in, would only last five years

Topics

UsernamePublicRestriction

Register

PS072045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel